Brigthpathe

Specifically, we are solving the issue of eye floaters in older adults.   We have found a drug, already approved by the FDA, that can almost completely clear up eye floaters. Eye floaters are small, shadowy shapes that appear in a person's vision and can be bothersome. This condition affects over 97 million Americans, and experts believe that more than 70% of people worldwide will experience eye floaters, especially after they turn 55.

This discovery is just one example of how our A.I. models can transform the field of medicine. These advanced A.I. systems analyze vast amounts of data and see connections between untedded side effects in other studies and in some cases point us to be able to predict how existing medicines can be used to treat different health issues. This process is not only faster but also much cheaper than traditional methods.

By using A.I., we can save tens of millions of dollars in the costs of developing new treatments. Normally, developing a new drug can take years and cost a lot of money because it involves a lot of research, testing, and regulatory approval. Our approach speeds up this process by using drugs that are already approved. This means they have been deemed safe and effective for use, which eliminates a lot of the preliminary steps usually needed.

What makes our platform special is that it's designed to be very efficient. Our AI model is adept at finding positive connections between unintended side effects between unrelated studies. This not only accelerates the overall drug discovery process but also reduces the financial risks associated with drug development.

The potential of our A.I. models goes beyond just finding new uses for old drugs. They can also help in understanding diseases better and developing entirely new treatments. As we continue to improve our technology, we expect to make even more breakthroughs that can benefit patients worldwide.

In summary, our work is about using smart technology to make healthcare better and more affordable. We are proud to be at the forefront of this innovative field, helping to bring new solutions to people who need them, while also cutting down on the time and money it takes to bring these solutions to market.

We've made an exciting discovery with one of our drug projects. We found a medication that can dissolve eye floaters. Eye floaters are those tiny spots or threads that drift through your vision, especially noticeable when you look at something bright like the sky or a computer screen. They are usually harmless but can be annoying and distracting.

Our discovery is special because this drug doesn't just clear the floaters you already have—it also helps slow down the creation of new ones temporarily. This means that not only can people see clearer without the floaters, but they might also have fewer floaters appear for a while.

The drug we're working with is already approved by the FDA, which means it has been tested and found safe for other uses. By finding a new use for this drug, we can help people faster and more safely than if we were starting from scratch with a brand-new drug. This is a big step forward in making sure everyone can have clear and comfortable vision without the bother of floaters, using a solution that's already well understood by doctors.

Link to our Case Study:  https://brightpathe.com/wp-content/uploads/2024/04/Brightpathe-Case-Study-.pdf

Our solution primarily benefits older adults, especially since most people who experience eye floaters are 55 years old and older. Eye floaters can be more than just a minor annoyance for the elderly; they can significantly interfere with daily activities like reading, driving, and other tasks that require clear vision. By providing a drug that dissolves these floaters and slows their production, we can greatly improve the quality of life for older individuals. They can enjoy clearer vision, which is crucial for maintaining independence and overall well-being as they age.

Additionally, our solution is particularly beneficial for people with limited financial resources. The standard treatment for severe eye floaters is a surgery called vitrectomy. This procedure involves removing the vitreous gel from the eye and replacing it with a gas bubble. Not only is this surgery invasive and carries risks such as infections and retinal detachment, but it is also very expensive. Many people, especially those without extensive health insurance or in lower-income brackets, cannot afford such a procedure.

Our drug provides a much more accessible alternative. It's less invasive, as it simply involves taking medication, and it's significantly cheaper than undergoing surgery. This makes it a viable option for many who would otherwise have to live with the discomfort and visual impairment caused by floaters. Thus, our solution not only enhances the quality of life by improving vision but also does so in a way that is affordable and accessible to everyone, particularly benefiting the elderly and financially disadvantaged populations.

I believe my team and I are uniquely qualified to bring this solution to the people who need it most because of our close ties and personal experiences with the challenges they face. As the Team Lead, I have a deep personal connection to the issues we are addressing, which makes this project more than just a job for us—it’s a mission.

Firstly, I suffer from eye floaters myself, which started after an injury I sustained while serving in the army. Living with this condition has given me a firsthand understanding of the frustration and difficulties it causes. This personal experience motivates me every day to find a solution that can help others see clearly and live better.

Additionally, my journey into the world of disease research began nine years ago when my son was diagnosed with a rare genetic chromosomal deletion known as 2p16-3. Watching him face these challenges sparked my commitment to researching rare diseases, trying to find better treatments for conditions that often go unnoticed by the broader medical community.

My own battle with cancer deepened my resolve. It opened my eyes to how many diseases don't get the attention or funding they desperately need. This experience taught me the importance of focusing on underrepresented health issues and fueled my passion for making a difference.

Our team is not just made up of researchers; we are also members of the communities we serve. We understand the struggles because we live them. This connection drives our commitment to not only develop effective solutions but to ensure they are accessible and affordable.

In designing and implementing our drug for eye floaters, we actively involve the community at every step. We listen to their experiences and incorporate their feedback to ensure our solution truly meets their needs. This includes discussions with elderly individuals who are most commonly affected by floaters, as well as with veterans who may have similar experiences to mine.

Our approach is also shaped by our understanding that many people cannot afford expensive treatments. Knowing that the alternative to our drug is a costly and invasive surgery, we are committed to providing a safer, less expensive option that can be accessed by people regardless of their financial situation.

By merging our personal insights with direct input from the community, we ensure our solution is not only scientifically sound but also compassionate and tailored to the real-life needs of those it aims to help. Our team’s unique blend of personal experience and professional expertise makes us the right people to bring this much-needed solution to those suffering from eye floaters, especially the elderly and economically disadvantaged. We’re not just developing a treatment; we’re striving to improve lives and make a lasting impact.

We've successfully built our A.I. model, and it has already helped us discover our first drug. Right now, we are taking important steps to protect our discovery. We are in the process of patenting the drug, which means we are getting a special permission that allows only us to make and sell our drug for a certain period of time. This helps make sure that our hard work is protected and that we can manage how the drug is used to help people.

At the same time, we are reaching out to larger pharmaceutical companies and governments in other countries to form partnerships. These partnerships are crucial because they will help us bring our drug to more people around the world. Big pharmaceutical companies have the resources and experience to produce and distribute medicines on a large scale. By working with them, we can make sure that our drug is made with the highest quality and gets to those who need it in a safe and efficient way.

Working with foreign governments is also important. It can help us understand different countries' rules and needs, so we can make our drug available in those places. These governments can also support us in reaching people in their countries who need our treatment.

By patenting our drug and forming these partnerships, we are making strong moves to bring our innovative solution to as many people as possible. This is how we plan to make a big difference in the health of people all over the world.

We are applying to the SOLVE competition because we believe it is a fantastic opportunity to collaborate with a diverse community that is dedicated to solving important global challenges. Our team has developed an innovative solution using A.I. to find new uses for FDA-approved drugs, specifically a drug that can significantly improve the treatment of eye floaters, a common issue that affects many, especially the elderly. While we have made great progress, there are several challenges that we face, and we believe that SOLVE can help us overcome them.

Firstly, technical support is crucial for us. As our solution relies heavily on A.I., having access to advanced technology and expert advice can help enhance our model’s accuracy and efficiency. SOLVE’s network of tech experts could provide the guidance needed to refine our algorithms and ensure they perform well on a larger scale.

Secondly, we face legal and regulatory barriers. Patenting a drug and navigating the complex regulatory pathways for drug approval in different countries can be daunting. Through SOLVE, we hope to connect with legal experts who can offer advice and help streamline this process, ensuring our drug can reach the market faster and comply with international standards.

Thirdly, cultural and market barriers are significant as we aim to introduce our drug to global markets. Understanding diverse health care systems and cultural attitudes towards medical treatment is essential. SOLVE’s global community could provide insights into various markets, helping us tailor our approach to different regions and cultures effectively.

Moreover, SOLVE can help us find the right partnerships. While funding is always helpful, our main goal in applying to SOLVE is not just to raise funds. We are looking for partnerships with pharmaceutical companies, governments, and healthcare providers that can help us produce, distribute, and deliver our drug to those who need it most. The SOLVE community is ideal for fostering these kinds of partnerships, offering both monetary and non-monetary support to help us scale our solution.

In conclusion, we see SOLVE as a perfect fit for advancing our project. Its emphasis on collaboration and its broad network of experts and partners align perfectly with our needs. By participating in SOLVE, we aim to leverage these resources to make our solution more effective and accessible worldwide, ultimately improving healthcare outcomes for millions of people.

Our solution is innovative because it uses artificial intelligence (AI) to find new uses for drugs that are already approved by the FDA. This approach is different and significantly improved compared to traditional methods of drug development for several reasons:

Speed and Efficiency: Normally, developing a new drug can take many years and a lot of money. Researchers have to start from scratch, testing thousands of compounds to see which ones might work. Our method skips many of these steps because we are using drugs that have already been tested and approved for safety. Our AI quickly scans existing data to find potential new uses for these drugs, speeding up the process of bringing treatments to patients.

Safety and Reduced Risk: Since the drugs we are working with are already approved, we know they are safe for people to use. This reduces the risks involved in trying new treatments. It also makes it easier to get approval to use these drugs for new purposes, as there is already a lot of safety data available.

Cost-Effective: Our approach is also more cost-effective. Drug development is typically very expensive, partly because many compounds fail during the expensive testing phases. By repurposing drugs, we reduce the amount of new testing needed and make better use of the investments already made in developing these drugs.

Impact on the Healthcare Market: Our solution could change the healthcare market by making treatments available faster and at a lower cost. This can be especially important for diseases that don't have effective treatments yet. It could lead to a shift in how pharmaceutical companies think about drug development, encouraging more focus on repurposing existing drugs rather than only creating new ones.

Catalyzing Broader Impacts: Our use of AI could inspire other companies and researchers in the healthcare field to also adopt similar technologies. Seeing the success of our approach might encourage more innovation in drug repurposing and AI applications in medicine. This could lead to more effective treatments across a range of diseases, improving health outcomes globally.

Changing the Landscape: Finally, our solution has the potential to change the landscape of medical treatment. By demonstrating that effective new treatments can be found through AI and drug repurposing, we could help shift the focus of research and development in the pharmaceutical industry. This could lead to more sustainable practices in healthcare, where maximizing the use of existing resources becomes as important as inventing new ones.

In conclusion, our solution is innovative not just because it uses new technology, but because it applies this technology in a way that could transform the entire process of how we find and develop treatments for health problems. This could lead to significant improvements in how quickly and affordably we can help people with various diseases.

Our solution aims to use artificial intelligence (AI) to find new uses for drugs that are already approved by the FDA. Here's a simple breakdown of how and why we expect it to make a positive impact:

Activity: We use AI to analyze lots of data about existing drugs. This includes information about what the drugs do, their ingredients, and any side effects they have. Our AI model looks for ways these drugs could help treat other diseases or health issues that they weren't originally designed for.

Immediate Outputs: The immediate result of our activity is that we identify potential new uses for these drugs. For example, we discovered a drug that could treat eye floaters effectively, which was not its original use. By doing this, we can quickly offer new treatment options without the long process and high cost of developing a brand new drug.

Longer-term Outcomes: Over time, these new uses for old drugs can be approved and become available to patients. This means people can get effective treatments faster, which can greatly improve their quality of life. Also, because these drugs are already approved for safety, the risk to patients is lower compared to trying a completely new drug.

Evidence to Support Our Links: Our approach is supported by previous research that shows AI can successfully identify new drug uses (this is known as drug repurposing). For instance, there are documented cases where drugs approved for one purpose were later found to be effective for something completely different, like using a diabetes drug to treat certain types of cancer. Our own tests with our AI model also show that it can accurately predict drug repurposing opportunities.

Impact on the Problem: By finding new uses for existing drugs, we can address health problems more quickly and with less risk than developing new drugs from scratch. This is especially important for conditions like eye floaters, which affect millions but have limited treatment options. Our solution can make a big difference for these people by providing new, safe, and accessible treatments.

In summary, our AI-driven approach to repurpose drugs is not only innovative but also practical. It shortens the timeline for treatments to reach patients and reduces the costs and risks associated with drug development. This can lead to better health outcomes for a wide range of conditions, benefiting individuals and healthcare systems alike.

Our main impact goal for our solution is to improve the quality of life for people suffering from eye floaters by providing a safe, effective, and accessible treatment. This goal guides all our efforts and helps us focus on making a real difference in the lives of those affected by this condition.

How We Measure Progress:

1. Number of Patients Treated: One of the primary indicators we use to measure our progress is the number of patients successfully treated with our repurposed drug. By tracking how many people use our treatment and experience relief from eye floaters, we can see how effective our solution is at solving the problem it's meant to address.

2. Reduction in Symptoms: We also measure the reduction in symptoms experienced by patients. This involves regular surveys where patients report changes in the severity and frequency of their eye floaters after using our drug. Improvements reported by patients help us understand how well the treatment is working.

3. Patient Satisfaction: Another key indicator is patient satisfaction. We collect feedback through follow-up surveys to learn about patients' overall satisfaction with the treatment and any side effects they may have experienced. High satisfaction rates and low incidence of side effects indicate that our treatment is not only effective but also well-tolerated.

4. Accessibility of Treatment: We aim to make our treatment accessible, especially to those who cannot afford expensive surgeries. To measure this, we track the distribution of our drug, focusing on its availability in underserved and low-income areas. Our goal is to ensure that our solution reaches those who need it most, regardless of their economic status.

5. Cost Savings: Since our drug repurposing method reduces the cost of drug development, we monitor the cost savings achieved and how these savings are passed on to patients. Lower treatment costs compared to traditional surgeries like vitrectomy are a good indicator that our solution is economically beneficial.

Alignment with UN Sustainable Development Goals:

Our solution aligns with several UN Sustainable Development Goals (SDGs), such as Goal 3: Good Health and Well-being. We use indicators from this goal, such as the proportion of the population with access to affordable healthcare services and the prevalence of diseases, to guide our impact measurements. By tracking these indicators, we can ensure our solution contributes to broader global health objectives.

In summary, our impact goals focus on effectively treating eye floaters, improving patient satisfaction, and making our solution accessible and affordable. By using specific indicators to measure our progress, such as the number of patients treated, symptom reduction, patient satisfaction, treatment accessibility, and cost savings, we can evaluate the success of our solution and continue to improve it. These measurements help us stay on track toward having a transformational impact on people's lives.

Our solution is powered by artificial intelligence (AI), specifically a type of AI called machine learning. Machine learning is a modern technology that allows computers to learn from data and make decisions without being directly programmed for each task. Here’s how it works for our solution:

We use AI to analyze huge amounts of information about different drugs that have already been approved by the FDA for safety. The AI looks for patterns and connections that humans might not easily see. For example, it can discover that a drug designed to treat one disease might also be effective in treating another condition, like eye floaters.

Our AI model goes through many pieces of data about drug components, how they work, and their effects on the body. It uses this information to predict which drugs could be repurposed to treat new health problems. This approach is much faster and less expensive than traditional drug discovery methods, which involve a lot of laboratory work and testing.

By using AI, we can find new uses for old drugs quickly and safely, bringing new treatments to patients faster and helping more people. This technology is a powerful tool that benefits both people and the planet by reducing the need for new drug production and minimizing waste.

We also share our AI model on our website, allowing anyone to see how it works and explore its capabilities. This openness helps educate others and spread knowledge about how AI can be used to solve health challenges. In this way, our technology not only finds new treatments but also inspires innovation and learning in others.

Our application is successful, and we've proven it by using our A.I. model to discover our first effective drug. To show everyone how our technology works, we have provided a version of our A.I. model on our website that anyone can use. This allows people to see firsthand how our system operates and understand its capabilities.

By making our A.I. model available online, we are opening up the opportunity for others to explore its features and learn about the innovative methods we use to find new uses for existing drugs. This transparency helps build trust and showcases the effectiveness of our approach in the field of drug discovery. Our goal is to demonstrate that our solution not only works but is accessible and easy to understand, making it a valuable tool for improving healthcare.

Our team is small but mighty, consisting of just two dedicated individuals. Despite our limited size, we bring a wealth of passion and expertise to our project.

We have been working in this space over 9 years, but on this problem for about a year.

Our team is small, but we are deeply committed to fostering diversity, ensuring equity, and creating an inclusive environment where all team members feel valued and empowered. Currently, our team consists of myself, a Black man, and Abbey, a woman. This diversity in our small team brings different perspectives and experiences that enrich our work and strengthen our problem-solving capabilities.

We understand the importance of expanding these principles as our team grows. Our goals for becoming more diverse and inclusive include actively seeking team members from varied cultural, racial, and educational backgrounds. We believe that a more diverse team will enhance our creativity and the relevance of our solutions to a broader audience.

To minimize barriers to opportunity, we will ensure equitable access to professional development and leadership opportunities within our team. We will strive to make sure everyone feels their voice can be heard and that their contributions are recognized and valued. This will include regular check-ins and feedback sessions where team members can express their needs and concerns.

We will establishing hiring practices that are fair and open, promoting job postings in diverse networks, and creating a work environment that supports work-life balance and respects personal and cultural practices.

In summary, as our team expands, we will remain committed to these principles of diversity, equity, and inclusion, aiming to create a workplace that reflects these values and enhances our collective ability to address the challenges we aim to solve.

Our business model is centered around using artificial intelligence (AI) to repurpose FDA-approved drugs for new medical uses, focusing initially on treating eye floaters—a common issue particularly affecting older adults. Here’s how our model works:

Key Customers and Beneficiaries: Our primary customers are healthcare providers and pharmaceutical companies interested in expanding the applications of existing drugs. The direct beneficiaries are patients suffering from conditions like eye floaters, who gain access to more affordable and quickly available treatment options.

Products and Services: We provide a valuable service by identifying new therapeutic uses for approved drugs. This not only speeds up the process of bringing treatments to market but also reduces the costs associated with drug development. Our AI model analyzes vast datasets to predict which drugs can be effectively repurposed, reducing the guesswork and resource expenditure typically involved in pharmaceutical research.

Delivery of Products/Services: Our service is delivered through partnerships with pharmaceutical companies and healthcare providers. We license our AI-driven findings to these organizations, who then take the lead on clinical trials, production, and distribution. This allows us to focus on our core competency—AI and data analysis—while leveraging our partners' resources and expertise in drug development and marketing.

Value Proposition: Customers (pharmaceutical companies and healthcare providers) want our services because they can reduce the time and cost of bringing new treatments to market. Our ability to quickly identify new uses for existing drugs is particularly valuable in today’s fast-paced medical environment, where the demand for new treatments is high and the pressure to reduce costs is ever-present.

Patients, the end beneficiaries, need our product because it provides them with more treatment options that are both effective and potentially safer, given that the drugs have already passed initial safety approvals. This is especially important for conditions that are currently underserved by existing medical solutions, such as eye floaters.

In summary, our business model leverages advanced AI technology to provide high-value, low-cost solutions in the pharmaceutical industry, satisfying the needs of both our commercial partners and the patients they serve. By focusing on repurposing existing drugs, we offer a faster, cheaper, and safer route to treatment development, addressing unmet medical needs and improving patient care.

Our plan for financial sustainability centers on licensing our patents to larger pharmaceutical companies. This strategy involves leveraging the innovative drug uses we discover through our AI platform and securing patents for these uses, which then become valuable assets. Here's how we are implementing this strategy and the evidence of its success so far:

Licensing Model: We generate revenue by licensing the rights to use our patents to pharmaceutical companies. These companies pay us a licensing fee, which can include an upfront payment and ongoing royalties based on the sales of the drug for its new use. This model is beneficial for both parties; it allows us to profit from our research and discoveries without bearing the costs of drug production, marketing, and distribution, while pharmaceutical companies get access to new markets and treatment options without the initial research and development risk.

Steps for Implementation:

1. Patent Protection: We secure patents for the new drug applications we discover. This legal protection is crucial as it prevents other companies from using our discoveries without permission.
2. Partnership Development: We actively seek partnerships with pharmaceutical companies that have the capability and interest in bringing these new treatments to market. These partnerships are often facilitated through industry conferences, direct outreach, and existing professional networks.
3. Negotiation of Terms: We negotiate the terms of licensing agreements to ensure they are mutually beneficial. The terms typically include details about the payment structure, the scope of the license, and the duration of the agreement.

Evidence of Success: So far, our approach has shown promising results. We have successfully received a provisional patent for our first drug repositioning discovery and are seeking more secured patents.  We have received and LOI from online pharmacy.  While these negotiations are ongoing, the interest from companies validates our business model and the demand for our AI-driven discoveries. Furthermore, the feedback we've received has been overwhelmingly positive.

Future Plans for Sustainability: To enhance our financial sustainability, we plan to:

• Expand our AI capabilities to increase the pipeline of discoverable drug reuses, thereby growing the number of potential licensing opportunities.
• Diversify our portfolio by exploring licensing deals in different therapeutic areas and geographical markets to spread risk.
• Consider strategic partnerships or alliances that could provide non-dilutive funding, such as research grants or co-development agreements.

In conclusion, our plan to achieve financial sustainability through patent licensing is grounded in a solid strategy that capitalizes on our unique AI capabilities and meets the needs of larger pharmaceutical companies looking for innovation with reduced R&D risk. Our initial success in securing interest and negotiations with potential licensees provides a strong foundation for future growth and sustainability.